Skip to main content
Top
Published in: Journal of Neurology 8/2020

01-08-2020 | Creutzfeldt-Jakob Disease | Original Communication

Familial Creutzfeldt–Jakob disease homozygous to the E200K mutation: clinical characteristics and disease course

Authors: Zeev Nitsan, Oren S. Cohen, Joab Chapman, Esther Kahana, Amos D. Korczyn, Shmuel Appel, Michael Osherov, Hanna Rosenmann, Ron Milo

Published in: Journal of Neurology | Issue 8/2020

Login to get access

Abstract

Objective

To characterize the demographic, clinical features and disease course of familial Creutzfeldt–Jakob disease (fCJD) patients homozygous to the E200K mutation.

Methods

The Israeli National CJD Database was screened for patients homozygous to the E200K mutation. Patients' demographic data, clinical presentation and neurological findings, tau protein levels in the cerebrospinal fluid (CSF) and EEG, were assessed.

Results

Ten homozygous E200K patients were identified (80% males). Average age of onset was 47.5 ± 6.1 years (range 40–56) and the average age of death was 49.3 ± 7. 7 years (range 42–63) with average disease duration of 27.7 ± 9.7 months (range 2–97). Initial clinical presentation included behavioral change in 4/10 patients, cognitive decline in 3/10 patients and focal neurological deficits in 2/10 patients. Throughout the disease course, the clinical signs in descending order of prevalence included cerebellar (70%), brainstem (60%), extrapyramidal (50%), pyramidal (50%), frontal lobe signs (30%), and disturbances of ocular motility (30%) Compared to the 228 heterozygous E200K fCJD patients, the 10 homozygous patients were significantly younger at disease onset (47.5 vs 59.7 years, p < 0.001), had a longer disease duration (27.7 vs 8.5 months, p < 0.001) and presented more frequently with behavioral changes as initial manifestation (4/10 vs. 34/228, p = 0.05).

Conclusions

Homozygous E200K fCJD patients are characterized by a relatively younger age of onset and longer disease duration. Behavioral changes as a presenting symptom were more common in homozygous patients and cerebellar dysfunction was the most common neurological manifestation throughout the disease course.
Literature
2.
go back to reference Knight RS, Will RG (2004) Prion diseases. J Neurol Neurosurg Psychiatry 75(Suppl 1):i36–42CrossRef Knight RS, Will RG (2004) Prion diseases. J Neurol Neurosurg Psychiatry 75(Suppl 1):i36–42CrossRef
3.
go back to reference Korczyn AD, Chapman J, Goldfarb LG, Brown P, Gajdusek DC (1991) A mutation in the prion protein gene in Creutzfeldt–Jakob disease in Jewish patients of Libyan, Greek, and Tunisian origin. Ann N Y Acad Sci 640:171–176CrossRef Korczyn AD, Chapman J, Goldfarb LG, Brown P, Gajdusek DC (1991) A mutation in the prion protein gene in Creutzfeldt–Jakob disease in Jewish patients of Libyan, Greek, and Tunisian origin. Ann N Y Acad Sci 640:171–176CrossRef
4.
go back to reference Kahana E, Alter M, Braham J, Sofer D (1974) Creutzfeldt–jakob disease: focus among Libyan Jews in Israel. Science 183:90–91CrossRef Kahana E, Alter M, Braham J, Sofer D (1974) Creutzfeldt–jakob disease: focus among Libyan Jews in Israel. Science 183:90–91CrossRef
5.
go back to reference Simon ES, Kahana E, Chapman J, Treves TA, Gabizon R, Rosenmann H et al (2000) Creutzfeldt–Jakob disease profile in patients homozygous for the PRNP E200K mutation. Ann Neurol 47:257–260CrossRef Simon ES, Kahana E, Chapman J, Treves TA, Gabizon R, Rosenmann H et al (2000) Creutzfeldt–Jakob disease profile in patients homozygous for the PRNP E200K mutation. Ann Neurol 47:257–260CrossRef
6.
7.
go back to reference Farnier M, Bruckert E (2012) Severe familial hypercholesterolaemia: current and future management. Arch Cardiovasc Dis 105:656–665CrossRef Farnier M, Bruckert E (2012) Severe familial hypercholesterolaemia: current and future management. Arch Cardiovasc Dis 105:656–665CrossRef
8.
go back to reference Sturtz FG, Latour P, Mocquard Y, Cruz S, Fenoll B, LeFur JM et al (1997) Clinical and electrophysiological phenotype of a homozygously duplicated Charcot–Marie-Tooth (type 1A) disease. Eur Neurol 38:26–30PubMed Sturtz FG, Latour P, Mocquard Y, Cruz S, Fenoll B, LeFur JM et al (1997) Clinical and electrophysiological phenotype of a homozygously duplicated Charcot–Marie-Tooth (type 1A) disease. Eur Neurol 38:26–30PubMed
9.
go back to reference Sobue G, Doyu M, Nakao N, Shimada N, Mitsuma T, Maruyama H et al (1996) Homozygosity for Machado–Joseph disease gene enhances phenotypic severity. J Neurol Neurosurg Psychiatry 60:354–356CrossRef Sobue G, Doyu M, Nakao N, Shimada N, Mitsuma T, Maruyama H et al (1996) Homozygosity for Machado–Joseph disease gene enhances phenotypic severity. J Neurol Neurosurg Psychiatry 60:354–356CrossRef
10.
go back to reference Cubo E, Martinez-Horta SI, Santalo FS, Descalls AM, Calvo S, Gil-Polo C et al (2019) Clinical manifestations of homozygote allele carriers in Huntington disease. Neurology 92:e2101–e2108PubMed Cubo E, Martinez-Horta SI, Santalo FS, Descalls AM, Calvo S, Gil-Polo C et al (2019) Clinical manifestations of homozygote allele carriers in Huntington disease. Neurology 92:e2101–e2108PubMed
11.
go back to reference WHO (1998) Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies: Report of the WHO consultation. In: World Health Organization: emerging and other communicable diseases, surveillance and control, Geneva, pp 9–11 WHO (1998) Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies: Report of the WHO consultation. In: World Health Organization: emerging and other communicable diseases, surveillance and control, Geneva, pp 9–11
12.
go back to reference Zilber N, Kahana E, Abraham M (1991) The Libyan Creutzfeldt–Jakob disease focus in Israel: an epidemiologic evaluation. Neurology 41:1385–1389CrossRef Zilber N, Kahana E, Abraham M (1991) The Libyan Creutzfeldt–Jakob disease focus in Israel: an epidemiologic evaluation. Neurology 41:1385–1389CrossRef
13.
go back to reference Cohen OS, Prohovnik I, Korczyn AD, Ephraty L, Nitsan Z, Tsabari R et al (2011) The Creutzfeldt–Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression. Acta Neurol Scand 124:368–374CrossRef Cohen OS, Prohovnik I, Korczyn AD, Ephraty L, Nitsan Z, Tsabari R et al (2011) The Creutzfeldt–Jakob disease (CJD) neurological status scale: a new tool for evaluation of disease severity and progression. Acta Neurol Scand 124:368–374CrossRef
14.
go back to reference Spudich S, Mastrianni JA, Wrensch M, Gabizon R, Meiner Z, Kahana I et al (1995) Complete penetrance of Creutzfeldt–Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. Mol Med 1:607–613CrossRef Spudich S, Mastrianni JA, Wrensch M, Gabizon R, Meiner Z, Kahana I et al (1995) Complete penetrance of Creutzfeldt–Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. Mol Med 1:607–613CrossRef
15.
go back to reference Chapman J, Ben-Israel J, Goldhammer Y, Korczyn AD (1994) The risk of developing Creutzfeldt–Jakob disease in subjects with the PRNP gene codon 200 point mutation. Neurology 44:1683–1686CrossRef Chapman J, Ben-Israel J, Goldhammer Y, Korczyn AD (1994) The risk of developing Creutzfeldt–Jakob disease in subjects with the PRNP gene codon 200 point mutation. Neurology 44:1683–1686CrossRef
16.
go back to reference Corato M, Cereda C, Cova E, Ferrarese C, Ceroni M (2006) Young-onset CJD: age and disease phenotype in variant and sporadic forms. Funct Neurol 21:211–215PubMed Corato M, Cereda C, Cova E, Ferrarese C, Ceroni M (2006) Young-onset CJD: age and disease phenotype in variant and sporadic forms. Funct Neurol 21:211–215PubMed
17.
go back to reference Boesenberg C, Schulz-Schaeffer WJ, Meissner B et al (2005) Clinical course in young patients with sporadic Creutzfeldt–Jakob disease. Ann Neurol 58:533–554CrossRef Boesenberg C, Schulz-Schaeffer WJ, Meissner B et al (2005) Clinical course in young patients with sporadic Creutzfeldt–Jakob disease. Ann Neurol 58:533–554CrossRef
Metadata
Title
Familial Creutzfeldt–Jakob disease homozygous to the E200K mutation: clinical characteristics and disease course
Authors
Zeev Nitsan
Oren S. Cohen
Joab Chapman
Esther Kahana
Amos D. Korczyn
Shmuel Appel
Michael Osherov
Hanna Rosenmann
Ron Milo
Publication date
01-08-2020
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 8/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-020-09826-z

Other articles of this Issue 8/2020

Journal of Neurology 8/2020 Go to the issue